15 December 2021
Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic
Lipid reformulation of anti-inflammatory compound MT1980 for POCD accelerating into clinic in 2022 … Manchester, UK, Dec 14, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised an additional £0.5 million to accelerate the development...
14 December 2021
INFEX Therapeutics agrees partnership with Colibri Scientific to provide services for RESP-X program
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with Colibri Scientific, to provide logistics and sample operational services for Infex’s RESP-X program. RESP-X is an anti-virulence therapy in-licensed from Japanese pharma company Shionogi. It is...
13 December 2021
Panthera Biopartners leads the way in the UK with specialist research sites for NASH and NAFLD studies
With access to leading hepatologists, biopsy theatres, fibroscans at specialist sites and ongoing mass screening programmes Panthera can help pharma and CROs find a treatment for this increasingly common, progressive, and life-threatening diseases. Non-Alcoholic steatohepatitis...
2 December 2021
INFEX Therapeutics scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech companies has announced a breakthrough in laboratory trials of a new drug to treat COVID-19 and new variants of the disease, such as the Omicron variant. Infex Therapeutics’ COV-X...
23 November 2021
Proveca sponsored clinical trial starts in France to evaluate the impact of its drug Sialanar®
The SALIVA (Sialanar® plus orAl rehabiLitation against placebo plus oral rehabilitation for chIldren and adolescents with seVere sialorrhoeA and neurodisabilities) study … In May 2021, the first child was enrolled into the SALIVA study, a trial sponsored by Proveca Pharma...
17 November 2021
Manchester Biogel and Resnova to sign a strategic agreement for the distribution in Italy of innovative solutions for 3D Cell Culture
Manchester BIOGEL and Resnova are pleased to announce today, their agreement for the exclusive distribution in Italy of fully synthetic scaffold products for 3D cell culture, organoid growth and 3D bioprinting products range. Manchester BIOGEL (MBG), is a British Company...
15 November 2021
Rinicare enters data sharing collaboration with Manchester University NHS Foundation Trust to further develop clinical risk prediction technology
Manchester-based health technology start-up Rinicare has signed a collaboration and data sharing agreement with Manchester University NHS Foundation Trust (MFT) to further develop its advanced clinical risk prediction technology platform, STABILITY. Rinicare’s clinical...
10 November 2021
Trio Healthcare takes leap forward in international growth strategy by opening first office in US
Trio Healthcare has made a significant step forward in its international growth strategy by opening its first office in the US. The team will be established in Princeton, New Jersey, and the move marks the first time the company will have a direct sales presence in the lucrative...
2 November 2021
Biofortuna relocates to purpose built facilities and more than doubles its capacity
Biofortuna, a specialist contract development and manufacturing partner to the IVD and point of care testing sectors, has more than doubled its manufacturing capacity following its relocation to new state-of-the-art facilities in Deeside, North Wales. The purpose-built...
1 November 2021
Panthera@theRutherford partnership commences first UK multicentre oncology trial in prostate cancer
Panthera@theRutherford clinical trial partnership has commenced the first UK multicentre oncology trial in prostate cancer with ten more oncology trials in the pipeline … The first multisite oncology trial undertaken by the independent sector in the UK has started treating its...